Vertex Pharmaceuticals Incorporated
VRTX
NASDAQ·Healthcare·Biotechnology·Mkt cap $139.0B
$541.69
▼ -1.07%
P/E
31.49
Mkt Cap
$139.0B
52-Wk Range
$374.17–$555.69
52-Week Range
$374.17 - $555.69
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 40.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Market leadership in cystic fibrosis treatments
- Advanced genetic research capabilities
- Strong intellectual property portfolio
- Diverse therapeutic pipeline
Bear Case
2 risks
- Low volatility (beta 0.3).
- Premium valuation to Biotech & Therapeutics peers
Growth
Stable outlook
Expanding rare disease treatment market
Value
Premium valuation to Biotech & Therapeutics peers
Momentum
Hot
+25.2% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying VRTX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 2, 2026
AUG 3, 2026
Reported EPS of $4.73 vs $4.74 consensus (-0.2% surprise). Revenue of $3.3B vs $3.2B expected (+3.2%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-0.2%
Revenue trend · last 8Q
—
+16%
+3%
+12%
+11%
+11%
+8%
+12%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$2.8B
$2.9B
$2.8B
$3.0B
$3.1B
$3.2B
$3.0B
$3.3B
Margins · last 8Q
Gross
85.3%
Operating
37.4%
Profit
33.0%
Wall Street consensus
15 analysts · 93% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
93%
Hold
7%
Sell
0%
Median Price Target
—
Latest: Bernstein · Aug 11, 2026
vs Industry
How VRTX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related